Strategic Initiative
Slingshot members are tracking this corporate initiative:
BioLineRx (BLRX) In-Licenses Novel Anti-Inflammatory Candidate for Dry Eye Syndrome (DES) from Hebrew University of Jerusalem
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BLRX |
|
|
||||
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Nov 21, 2016 Projected Implementation: Q4, 2016 Relevance Tracked Until: Q4, 2018
Related Projects
-
Don’t see a project related to the strategic initiative you care about?
Related Keywords
In-license, Anti-inflammatory Candidate, Dry Eye Syndrome, Des
